血清乙醇酸浓度:其在乙二醇暴露中的预后价值及与替代标志物的相关性
该系统评价纳入32项报告乙二醇暴露患者血清乙醇酸浓度的研究,分析其与急性肾损伤(AKI)、死亡的关系及与阴离子间隙、碱剩余、碳酸氢盐、pH的相关性。预后分析纳入133例患者的137例次,替代指标分析纳入150例患者的154例次;中位乙醇酸浓度11.2 mmol/L(85.1 mg/dL,范围0-38.0 mmol/L,0-288.8 mg/dL),93%使用解毒剂,80%接受体外治疗,49%发生AKI,13%死亡。预测AKI的最佳阈值为12.9 mmol/L(98.0 mg/dL,敏感性78.5%,特异性88.1%,阳性预测值86.4%,阴性预测值80.9%);AKI阴性预测值95%的阈值为6.6 mmol/L(50.2 mg/dL,敏感性96.9%,特异性62.7%)。预测死亡的最佳阈值为19.6 mmol/L(149.0 mg/dL,敏感性61.1%,特异性81.4%,阳性预测值33.3%,阴性预测值93.2%);死亡阴性预测值100%的阈值为8.3 mmol/L(63.1 mg/dL,敏感性100.0%,特异性35.6%)。乙醇酸与阴离子间隙相关性最好(R²=0.73),其次为碳酸氢盐(R²=0.57)、pH(R²=0.50)、碱剩余(R²=0.25),与乙二醇浓度无相关性(R²=0.00)。作者认为这些数据可辅助规划体外治疗和预后判断,并可能为疑似但未确诊乙二醇中毒患者等待
要点
- 乙二醇暴露患者血清乙醇酸浓度<8.3 mmol/L(63.1 mg/dL)时死亡阴性预测值100%(敏感性100.0%,特异性35.6%),提示死亡可能性不大。
- 预测AKI的最佳乙醇酸阈值为12.9 mmol/L(98.0 mg/dL),敏感性78.5%、特异性88.1%、阳性预测值86.4%、阴性预测值80.9%。
- AKI阴性预测值95%的乙醇酸阈值为6.6 mmol/L(50.2 mg/dL),敏感性96.9%、特异性62.7%。
- 预测死亡的最佳乙醇酸阈值为19.6 mmol/L(149.0 mg/dL),敏感性61.1%、特异性81.4%、阳性预测值33.3%、阴性预测值93.2%。
- 乙醇酸浓度与阴离子间隙相关性最好(R²=0.73),其次为碳酸氢盐(R²=0.57)、pH(R²=0.50)、碱剩余(R²=0.25),与乙二醇浓度无相关性(R²=0.00)。
适用人群与场景
- 人类乙二醇暴露患者,研究需报告测得的乙醇酸浓度;预后分析纳入133例患者的137例次,替代指标分析纳入150例患者的154例次。
诊断标准与关键阈值
- 预测AKI的最佳乙醇酸阈值为12.9 mmol/L(98.0 mg/dL),敏感性78.5%、特异性88.1%、阳性预测值86.4%、阴性预测值80.9%。
- AKI阴性预测值95%的乙醇酸阈值为6.6 mmol/L(50.2 mg/dL),敏感性96.9%、特异性62.7%。
- 预测死亡的最佳乙醇酸阈值为19.6 mmol/L(149.0 mg/dL),敏感性61.1%、特异性81.4%、阳性预测值33.3%、阴性预测值93.2%。
- 死亡阴性预测值100%的乙醇酸阈值为8.3 mmol/L(63.1 mg/dL),敏感性100.0%、特异性35.6%。
研究设计与关键结果
- 系统评价检索Medline/PubMed、EMBASE、Cochrane图书馆、会议论文集和参考文献列表,共鉴定1531篇文章,655篇可能符合条件,最终纳入32篇。
- 预后研究纳入133例患者的137例次,替代指标研究纳入150例患者的154例次;中位乙醇酸浓度11.2 mmol/L(85.1 mg/dL,范围0-38.0 mmol/L,0-288.8 mg/dL)。
- 93%的患者接受解毒剂治疗,80%接受体外治疗,49%发生AKI,13%死亡。
- 乙醇酸浓度与阴离子间隙相关性最好(R²=0.73),其次为碳酸氢盐(R²=0.57)、pH(R²=0.50)、碱剩余(R²=0.25),与乙二醇浓度无相关性(R²=0.00)。
证据类型、等级与局限
- 证据类型:系统评价。
- 作者结论:血清乙醇酸浓度可预测死亡(<8 mmol/L [61 mg/dL]时死亡可能性不大),阴离子间隙是乙二醇中毒背景下乙醇酸浓度的合理替代指标。
- 局限性:研究结果主要基于已发表的回顾性数据,这些数据存在各种局限性;需要进一步的前瞻性验证研究。
对床旁实践的改变
- 作者认为,这些数据可辅助临床医生规划体外治疗和进行预后判断。
- 作者认为,对于疑似但尚未确诊乙二醇中毒的患者,在等待进一步检测结果时,这些数据可能为推迟体外治疗提供一定保证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: Ethylene glycol poisoning manifests as metabolic acidemia, acute kidney injury and death. The diagnosis and treatment depend on history and biochemical tests. Glycolate is a key toxic metabolite that impacts prognosis, but assay results are not widely available in a clinically useful timeframe. We quantitated the impact of serum glycolate concentration for prognostication and evaluated whether more readily available biochemical tests are acceptable surrogates for the glycolate concentration.
OBJECTIVES: The objectives of this study are to 1) assess the prognostic value of the initial glycolate concentration on the occurrence of AKI or mortality in patients with ethylene glycol exposure (prognostic study); 2) identify surrogate markers that correlate best with glycolate concentrations (surrogate study).
METHODS: A systematic review of the literature was performed using Medline/PubMed, EMBASE, Cochrane library, conference proceedings and reference lists. Human studies reporting measured glycolate concentrations were eligible. Glycolate concentrations were related to categorical clinical outcomes (acute kidney injury, mortality), and correlated with continuous surrogate biochemical measurements (anion gap, base excess, bicarbonate concentration and pH). Receiver operating characteristic curves were constructed to calculate the positive predictive values and the negative predictive values of the threshold glycolate concentrations that predict acute kidney injury and mortality. Further, glycolate concentrations corresponding to 100% negative predictive value for mortality and 95% negative predictive value for acute kidney injury were determined.
RESULTS: Of 1,531 articles identified, 655 were potentially eligible and 32 were included, reflecting 137 cases from 133 patients for the prognostic study and 154 cases from 150 patients for the surrogate study. The median glycolate concentration was 11.2 mmol/L (85.1 mg/dL, range 0-38.0 mmol/L, 0-288.8 mg/dL), 93% of patients were treated with antidotes, 80% received extracorporeal treatments, 49% developed acute kidney injury and 13% died. The glycolate concentration best predicting acute kidney injury was 12.9 mmol/L (98.0 mg/dL, sensitivity 78.5%, specificity 88.1%, positive predictive value 86.4%, negative predictive value 80.9%). The glycolate concentration threshold for a 95% negative predictive value for acute kidney injury was 6.6 mmol/L (50.2 mg/dL, sensitivity 96.9%, specificity 62.7%). The glycolate concentration best predicting mortality was 19.6 mmol/L (149.0 mg/dL, sensitivity 61.1%, specificity 81.4%, positive predictive value 33.3%, negative predictive value 93.2%). The glycolate concentration threshold for a 100% negative predictive value for mortality was 8.3 mmol/L (63.1 mg/dL, sensitivity 100.0%, specificity 35.6%). The glycolate concentration correlated best with the anion gap (R2 = 0.73), followed by bicarbonate (R2 = 0.57), pH (R2 = 0.50) and then base excess (R2 = 0.25), while there was no correlation between the glycolate and ethylene glycol concentration (R2 = 0.00). These data can assist clinicians in planning treatments such as extracorporeal treatments and prognostication. Potentially, they may also provide some reassurance regarding when extracorporeal treatments can be delayed while awaiting the results of further testing in patients in whom ethylene glycol poisoning is suspected but not yet confirmed.
CONCLUSIONS: This systematic review demonstrates that the glycolate concentration predicts mortality (unlikely if <8 mmol/L [61 mg/dL]). The anion gap is a reasonable surrogate measurement for glycolate concentration in the context of ethylene glycol poisoning. The findings are mainly based on published retrospective data which have various limitations. Further prospective validation studies are of interest.
参考来源
- Roberts DM, Hoffman RS, Brent J, et al. The serum glycolate concentration: its prognostic value and its correlation to surrogate markers in ethylene glycol exposures. Clin Toxicol (Phila). 2022. PMID: 35323087. doi:10.1080/15563650.2022.2049811
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。